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Influenza A(H1N1)v virus was first identified in April 2009. A 
novel real-time RT-PCR for influenza A(H1N1)v virus was set up ad 
hoc and validated following industry-standard criteria. The lower 
limit of detection of the assay was 384 copies of viral RNA per 
ml of viral transport medium (95% confidence interval: 273-876 
RNA copies/ml). Specificity was 100% as assessed on a panel of 
reference samples including seasonal human influenza A virus 
H1N1 and H3N2, highly pathogenic avian influenza A virus 
H5N1 and porcine influenza A virus H1N1, H1N2 and H3N2 
samples. The real-time RT-PCR assay for the influenza A matrix 
gene recommended in 2007 by the World Health Organization 
was modified to work under the same reaction conditions as the 
influenza A(H1N1)v virus-specific test. Both assays were equally 
sensitive. Clinical applicability of both assays was demonstrated by 
screening of almost 2,000 suspected influenza (H1N1)v specimens, 
which included samples from the first cases of pandemic H1N1 
influenza imported to Germany. Measuring influenza A(H1N1)v 
virus concentrations in 144 laboratory-confirmed samples yielded 
a median of 4.6 log RNA copies/ml. The new methodology proved 
its principle and might assist public health laboratories in the 
upcoming influenza pandemic.
Introduction
Influenza A(H1N1)v virus was identified in humans in Mexico 
and the United States (US) in April 2009 [1] and has since 
spread worldwide [2]. The World Health Organization (WHO) 
declared pandemic alert stage 6 on 11 June 2009, indicating 
an ongoing influenza pandemic [3]. The transmissibility of the 
influenza A(H1N1)v virus was estimated to be higher than that of 
seasonal influenza viruses [4]. Influenza A(H1N1)v infections have 
been primarily seen among young and previously healthy adults 
suggesting that they are most vulnerable to infection. It remains 
speculative whether older people might have some level of cross-
protection from pre-existing antibodies [4]. Clinical presentation 
and severity remains unclear, but with the exception of cases in 
Mexico, most confirmed cases have been characterised by mild 
influenza-like illness [5]. However, a considerable proportion of 
patients reported vomiting or diarrhoea which is unusual in seasonal 
influenza [5]. To limit community or hospital transmission, as well 
as to initiate antiviral therapy in time as recommended by the 
WHO, the rapid detection of the virus in suspected cases remains 
crucial [6]. 
After the emergence of the H1N1 influenza pandemic no specific 
or well-validated diagnostic test was available. Rapid antigen-based 
tests for seasonal influenza seem to be compatible with pandemic 
H1N1 influenza, even though anecdotal reports exist on false-
negative test results [1]. In the clinical diagnosis of influenza, 
nucleic acid testing by RT-PCR has widely replaced traditional virus 
culture due to shorter turnaround times and increased sensitivity 
[7]. Broadly reactive RT-PCR assays are indeed capable of detecting 
influenza A(H1N1)v virus [1], but they may lack sensitivity and 
cannot differentiate between contemporary influenza A viruses and 
influenza A(H1N1)v virus [8]. 
Immediately after the recognition of the new virus, sequence 
information was made publicly available by the Global Initiative 
on Sharing Avian Influenza Data (GISAID) [9]. We used this 
information to design and distribute a real-time RT-PCR assay 
specific for influenza A(H1N1)v [10,11]. In parallel, a published 
screening assay was evaluated for its ability to detect both influenza 
A(H1N1)v and seasonal influenza A virus [12]. This second assay 
served as a confirmatory test for pandemic H1N1 influenza, 
as well as for discriminating seasonal influenza from influenza 
A(H1N1)v infection. Pre-validated and quality-confirmed sets of 
oligonucleotides for both assays were centrally distributed within 
a large network of laboratories within Germany, covering most 
university hospitals and many public health institutions [13,14]. 
On 27 April 2009, samples from the first imported case of 
pandemic H1N1 influenza in Germany were received before 
specific assays for pandemic H1N1 influenza became available. 
The diagnosis was therefore confirmed overnight by sequencing 
of initial amplification products from an assay not specific for 
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pandemic H1N1 influenza [8]. The second imported case in 
Germany occurred on the evening of 28 April, the day the assay 
was first distributed. This case was diagnosed primarily with the 
new assays within three hours of receipt of the specimen. Here 
we report technical and clinical performance of the novel set of 
diagnostic tests on a large panel of samples. 
Methods 
Patient samples from the H1N1 influenza pandemic
At the beginning of the pandemic, 106 samples from 106 
individual patients with acute onset of respiratory symptoms 
accompanied by fever and a recent travel history to countries 
with sustained human-to-human transmission of pandemic H1N1 
influenza were analysed with the novel pandemic H1N1 influenza 
real-time PCR assay as well as the general influenza A (matrix 
gene) screening assay. These samples were collected and analysed 
in Bonn, Freiburg, Hamburg, Marburg and Regensburg. One of 
these samples was from an imported laboratory-confirmed case 
of influenza A(H1N1)v infection (Patient 1), and one from the 
first patient with hospital-aquired influenza A(H1N1)v infection in 
Germany (Patient 2). Patient 1 was diagnosed in Hamburg. Patient 
2 was from Regensburg and had been infected by the first imported 
case to Germany [8]. 
A further 1,838 suspected cases were analysed at Bonn 
University Medical Centre later in the pandemic, until 30 July 
2009. Of those, 211 cases were laboratory-confirmed pandemic 
H1N1 influenza. A selection of 144 pandemic H1N1 influenza-
positive samples were used to determine virus concentrations in 
respiratory samples. 
Specimens included nasopharyngeal swabs in viral transport 
medium, sputum, broncho-alveolar lavage fluid, throat washes, as 
well as cell culture medium containing reference virus strains. Viral 
nucleic acid was extracted using the Viral RNA mini kit (Qiagen).
Pandemic H1N1 influenza-specific real-time RT-PCR assays
Real-time RT-PCR oligonucleotides for influenza A(H1N1)
v virus targeting the haemagglutinin (HA) gene were designed 
with Primer Express version 2 (Applied Biosystems) software. 
GenBank Accession number FJ966082 served as the template 
sequence. Several primer-and-probe combinations were evaluated 
experimentally to determine the most efficient combination.
A PCR reaction (One-step RT-PCR kit, Qiagen) of 25 μl for 
the pandemic H1N1 influenza specific assay contained: 5 
μl of RNA extract, 1x reaction buffer, 400 μM of each dNTP, 
40 ng/μl bovine serum albumine, 400 nM of primer H1SWS 
(CATTTGAAAGGTTTGAGATATTCCC; GenBank Accession 
Number FJ966082, nt 380-404), 400 nM of primer H1SWAs 
(ATGCTGCCGTTACACCTTTGT; nt 457-437), 200 nM of probe 
H1SWP (FAM-ACAAGTTCATGGCCCAATCATGACTCG-BBQ; nt 
409-435) and 1 μl of Enzyme Mix. All primers and probe were 
synthesised by TIB Molbiol, Berlin, Germany. Thermal cycling was 
done on a LightCycler 2.0 (Roche Diagnostics) instrument under 
the following conditions: 30 min at 50 °C; 15 min at 95 °C; 45 
cycles of 15 s at 94 °C; and 30 s at 60 °C.
The same protocol can be run on a Lightcycler 480 system 
(Roche Diagnostics) without loss of sensitivity (data not shown). 
No other commercial test kits were evaluated in this study.
General influenza A (MA) real-time RT-PCR
Published real-time PCR primers targeting the matrix (MA) 
gene of influenza A virus were used [12]. A PCR reaction 
(One-step RT-PCR kit, Qiagen) of 25 μl for the matrix assay 
contained 5 μl of RNA extract, 1x reaction buffer, 400 μM of 
each dNTP, 40 ng/μl bovine serum albumine, 400 nM of primer 
M_InfA F (AAGACCAATCCTGTCACCTCTGA; GenBank Accession 
number CY038773; nt 175-197), 400 nM of primer M_InfA R 
(CAAAGCGTCTACGCTGCAGTCC; nt 269-248), 200 nM of probe 
M_InfA TM (FAM-TTTGTGTTCACGCTCACCGT-BBQ; nt 215-234) 
and 1 μl of Enzyme Mix. Thermal cycling was done on a LightCycler 
2.0 (Roche Diagnostics) instrument under the following conditions: 
30 min at 50 °C; 15 min at 95 °C; 45 cycles of 15 s at 94 °C; 
and 30 s at 60 °C.
As above, the same protocol can be run on a Lightcycler 480 
system (Roche Diagnostics) without loss of sensitivity (data not 
shown). 
Construction of in vitro-transcribed RNA controls
A partial HA gene fragment from the virus isolated 
from Patient 1 was amplified using primers HA_InfA_
CaF1 (CAACAGACACTGTAGACACAG; GenBank Accession 
number FJ966082; nt 86-106) and HA_InfA_CaR1 
(TTCCATTGCGAATGCATATCTCGG; nt 825-802) and cloned into 
a pJET12 plasmid vector (Fermentas). The complete MA gene 
from the same virus was amplified using primers Matrix_Cal_F 
(TAACCGAGGTCGAAACGTACG; GenBank FJ969513; nt 11-31) 
and Matrix_Cal_R (TTACTCTAGCTCTATGTTGAC; nt 982-902) and 
ligated and cloned as described above. Plasmids were transcribed 
into RNA by means of a MEGAScript T7 in vitro transcription kit 
(Ambion) as described [15]. RNA in vitro transcripts were purified 
and quantified spectrophotometrically. Sequence integrity was 
checked by sequencing on an ABI 3100 automated sequencer 
(Applied Biosystems).
Determination of lower limit of detection
Initial experiments were done with RNA extracted from 
nasopharyngeal specimens of Patient 1. To exactly determine the 
lower limit of detection (LOD) of both real-time RT-PCR assays, 
different concentrations of HA RNA transcript as well as MA RNA 
transcript were spiked into viral transport medium, and RNA was 
extracted using the viral RNA mini kit (Qiagen). Influenza-negative 
swabs to account for patient derived matrix effects were not used 
since possible PCR inhibitors will most likely be efficiently diluted 
by the viral transport medium. Five replicates of each concentration 
were processed and analysed by the pandemic H1N1 influenza 
(HA RNA transcript) and the screening (MA RNA transcript) real-
time RT-PCR, respectively. Fractions of positive results for each 
concentration were subjected to probit regression analysis using 
the Statgraphics software package (Manugistics). 
Quantitive results for pandemic H1N1 influenza
Nasal and throat swabs from a selection of 144 cases of 
pandemic H1N1 influenza (see above) were used to determine 
influenza A(H1N1)v virus RNA concentrations in the H1N1 
influenza-specific (HA) real-time assay using in vitro-transcribed 
RNA as described [15]. An external curve was generated and cycle 
threshold values were transformed into log RNA copies/ml.
Results 
Pandemic H1N1 influenza-specific (HA) real-time RT-PCR assays
Tenfold serial dilution series of in vitro-transcribed HA RNA 
were tested in duplicates in the pandemic H1N1 influenza (HA) 
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RT-PCR (Figure 1A) and the general influenza A (MA) screening 
RT-PCR (Figure 1B), in order to determine the linear range of both 
real-time RT-PCR assays. The resulting end-points of detection in 
the pandemic H1N1 influenza (HA) RT-PCR were 1 and 5 RNA 
copies/μl in different experiments. A linear correlation between the 
F i g u r e  2
Probit analysis of pandemic H1N1 influenza (HA) real-time RT-PCR and general influenza A (MA) screening real-time 
RT-PCR
HA: haemagglutinin gene; MA: matrix gene.
Depicted are the observed proportion of positive test results in parallel experiments (square data points), as well as the derived predicted proportion of positive 
results (line) at a given input concentration of RNA. The centre line denotes the prediction, thin broken border lines are 95% confidence intervals.
F i g u r e  1
Linear range of pandemic H1N1 influenza (HA) real-time RT-PCR and general influenza A (MA) screening real-time RT-PCR
HA: haemagglutinin gene; MA: matrix gene.
Observed cycle thresholds are plotted against log RNA concentration (square points). Thick centre lines represent the prediction line, thin lines the 95% 
confidence intervals. 
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log starting copy number and threshold cycle was achieved from 
2.67 x 102 RNA copies/μl to at least 2.67 x 108 RNA copies/μl. 
The slope was calculated as 3.15 for the pandemic H1N1 
influenza (HA) assay. Based on the slope value, PCR efficiency 
was calculated to be 1.0 (according to the PCR amplification 
formula E=10(1/slope)-1; E being the PCR efficiency), indicating 
100% efficient PCR amplification. 
The 95% LOD was determined next. This common technical 
specification indicates the concentration down to which an assay 
will detect the analyte with at least 95% probability. To generate 
defined reference material that mimics clinical samples, different 
concentrations of in vitro-transcribed RNA were spiked into viral 
transport medium in which swabs are routinely received in the 
laboratory. Each analyte concentration was tested in five replicate 
reactions in each RT-PCRassay and yielded a 95% LOD of 384 RNA 
copies/ml (95% CI: 273-876 RNA copies/ml) for the pandemic 
H1N1 influenza (HA) assay (Figure 2A). 
T a b l e  2
Specificity testing of influenza specimens of porcine and human origin by MA broad-range assay and pandemic H1N1 
influenza-specific assay
Real-time RT-PCR result
Influenza virus specimen MA assay Pandemic H1N1 influenza assay
1 A/Swine/Hannover/1/81(H1N1) + -
2 A/Swine/Germany/2/81 (H1N1) + -
3 A/Swine/Italy/21599-3/03 (H1N1) + -
4 A/Swine/Borkum/1832/00 (H1N2) + -
5 A/Swine/Italy/30019-2/07 (H1N2) + -
6 A/Swine/Italy/65260-11/06 (H3N2) + -
7 A/Bayern/7/95 (H1N1) + -
8 A/Beijing/262/95 (H1N1) + -
9 A/Brazil/11/78 (H1N1) + -
10 A/Moscow/10/99 (H3N2) + -
11 Influenza A clinical samples 2008-9 (n=120)* + -
Influenza quality assessment samples
12 A/Fukushima/141/06 (H1N1) + -
13 A/New Caledonia/20/99 (H1N1) + -
14 A/Brisbane/10/07 (H3N2) + -
15 A/Brisbane/59/07 (H3N2) + -
16 A/California/7/04 (H3N2) + -
17 A/Wisconsin/67/06 (H3N2) + -
18 A/duck/Vietnam/TG24-01/05 (H5N1) + -
19 A/whooper swan/Germany/R65-2/06 (H5N1) + -
20 B/Florida/4/06** - -
21 B/Malaysia/2506/04** - -
22 B/Shanghai/361/02** - -
MA: matrix protein gene.
+ depicts a positive,  – a negative result.
*All 120 samples tested positive in the MA and negative in the pandemic H1N1 influenza assay.
**All influenza B samples tested positive in an influenza B- specific RT-PCR (data not shown).
T a b l e  1
Serial tenfold dilutions of RNA extracted from Patient 1 
tested by the MA broad-range assay as well as the pandemic 
H1N1 influenza-specific real-time RT-PCR
Log10 dilution series RNA, Patient 1
10-2 10-3 10-4 10-5 10-6 10-7
MA assay + + + + - -
Pandemic H1N1 influenza assay + + + + - -
MA: matrix protein gene.
+ indicates a positive result, – denotes a negative result.
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General influenza A (MA) real-time RT-PCR
For confirmation of influenza A virus detection, oligonucleotides 
from several published and evaluated RT-PCR assays were checked 
against the genome sequence of influenza A(H1N1)v virus. One 
assay developed by Ward et al. [12], was targeted against the MA 
gene. This assay had been recommended by the WHO for general 
influenza A virus screening, including avian influenza A virus 
(H5N1), matched the influenza A(H1N1)v virus sequence except for 
one base pair mismatch (C-T) 13 nucleotides from the 3´-end of the 
plus strand primer [16]. This mismatch was considered uncritical. 
The assay was optimised in order to comply with the same cycling 
conditions as the pandemic H1N1 influenza (HA) assay, so that 
both assays could be run in parallel in one LightCycler instrument. 
Serial dilution series of patient RNA were tested with both assays. 
As shown in Table 1, both assays were equally sensitive.
Using in vitro-transcribed MA RNA, the MA assay yielded an end-
point dilution sensitivity of 13 RNA copies per μl. The linear range 
extended from 1.28x102 RNA copies/μl to at least 1.28x108 RNA 
copies/μl. The slope was calculated as 3.35, and PCR efficiency 
was 0.99 (Figure 1). In a probit analysis as described above, the 
MA-based broad range assay showed a 95% LOD of 570 RNA 
copies/ml (95% CI: 397-1,232 RNA copies/ml) (Figure 2). 
Specificity of the pandemic H1N1 influenza (HA) assay
Specificity of the H1-based pandemic H1N1 influenza assay 
was confirmed on a panel of 21 stored clinical samples containing 
adenovirus (n=1), respiratory syncytial virus (RSV)-A (n=5), RSV-B 
(n=2), human coronavirus OC43 (n=1), human coronavirus 229E 
(n=3), human coronavirus NL63 (n=1), human metapneumovirus 
(n=1), parainfluenzavirus 3 (n=1) and entero-/rhinovirus (n=6) 
as assessed by xTAG Respiratory Viral Panel (Luminex; authors’ 
unpublished data). As expected, none of these pathogens reacted 
with the pandemic H1N1 influenza real-time RT-PCR indicating its 
high specificity. The MA-based broad range assay was not evaluated 
on this panel but demonstrated its specificity as described. [12]. 
Because of the porcine origin of pandemic H1N1 influenza [17], 
the assay was also tested on cell culture supernatants containing 
porcine influenza A virus reference samples (Table 2, rows 1-6). 
To exclude cross-reactivity with human influenza viruses, we 
tested cell culture supernatants of human influenza virus strains 
(Table 2, rows 7-10) as well as 120 original clinical samples from 
patients with seasonal influenza A virus infection from the 2008-9 
season, including H1N1 and H3N2 viruses (Table 2, row 11). All 
of these were negative in the pandemic H1N1 influenza (HA) assay 
and positive in the MA-based broad-range assay (shown in Table 2). 
In addition, 30 stored samples from recent quality assessment 
tests for influenza virus detection were evaluated (Table 2, rows 
12-22). None of these materials, which included various dilutions 
of contemporary human influenza A(H1N1, H3N2) as well as avian 
influenza A(H5N1) and influenza B virus samples yielded a positive 
result with the pandemic H1N1 influenza (HA) assay. All influenza 
A samples were positive in the general influenza A MA-based assay. 
Clinical evaluation
A preliminary clinical evaluation was done in five public 
health and university laboratories in Germany. By mid-May 2009 
samples from 106 individual patients suspected on clinical and 
epidemiological grounds to have aquired influenza A(H1N1)v 
infection had been analysed with the new assays. Of these 106 
samples, 102 gave negative results in both assays. Three of the four 
remaining samples tested positive in the MA-based assay, but were 
negative in the HA-based pandemic H1N1 influenza assay. After 
to further confirmatory testing, these three samples turned out to 
be human seasonal influenza A virus infections (data not shown). 
The last sample was positive in both assays. This patient (Patient 
1) was preliminary classified as having acute influenza A(H1N1)
v infection. She had a recent travel history to Mexico and sought 
medical treatment for fever and acute respiratory symptoms in 
Hamburg on 28 April 2009. Influenza A(H1N1)v infection was 
confirmed by the National Influenza Reference Centre at the 
Robert-Koch Institute (RKI), Berlin. 
Material from another confirmed case (Patient 2) was provided 
retrospectively for testing with both assays. This patient had not 
reported a recent travel history but shared a hospital room with 
the first imported case of pandemic H1N1 influenza in Germany 
[8]. The patient had only very mild symptoms. Both assays reacted 
clearly positive.
Later in the pandemic, further samples of suspected influenza 
A(H1N1)v infection were analysed with the new assay at Bonn 
University Medical Center, so far 1,838 samples. Among those, 221 
confirmed cases of pandemic H1N1 influenza have been identified 
as of 30 July. 
Quantitative results for pandemic H1N1 influenza
Viral RNA concentrations were measured in samples from 144 
laboratory-confirmed cases of pandemic H1N1 influenza for whom 
RNA preparations were available at Bonn University Medical Center. 
A median of 4.6 influenza A(H1N1)v virus log RNA copies per ml 
of viral transport medium was determined in the pandemic H1N1 
influenza-specific (HA) assay (range 2.1-7.9 log RNA copies/ml), 
indicating rather low virus concentrations.
Discussion
A real-time RT-PCR specific for influenza A(H1N1)v virus was set 
up immediately after first sequence information became available, 
and evaluated thoroughly from a technical and clinical point of 
view. 
In the currently evolving influenza pandemic, rapid and reliable 
case identification remains crucial to limit extensive transmission 
and to initiate therapy [18]. The performance of antigen-based tests 
for pandemic H1N1 influenza has not been extensively evaluated 
so far, but anecdotal reports do exist of false negative test results in 
confirmed cases of pandemic H1N1 influenza [19]. A further issue 
with antigen-based tests is the fact that they do not discriminate 
between seasonal influenza A virus strains and influenza A(H1N1)
v virus strains. The concurrence of the first wave of the pandemic 
H1N1 influenza and regular seasonal influenza in the southern 
hemisphere poses a risk of intra-human reassortation, making it 
highly relevant to discriminate between viruses by laboratory testing 
[20]. 
Real-time RT-PCR has proven highly effective in the detection 
of seasonal human influenza [21]. First reports on clinical cases in 
which influenza A(H1N1)v virus was detected by real-time RT-PCR 
have become available, but the assays used so far had not been 
validated thoroughly from a technical point of view [19,22,23]. 
Our study presents the first fully validated real-time RT-PCR for 
pandemic H1N1 influenza. Its LOD at 384 RNA copies/ml (95% 
LOD, probit analysis) is comparable to that of commercial test 
kits [21,24]. Specificity was proven on a comprehensive panel of 
6  EUROSURVEILLANCE  Vol .  14 ·  Issue 36 ·  10 September  2009 ·  www.eurosurveillance.org
120 clinical samples containing contemporary human influenza 
A and B viruses, on reference specimens from an external quality 
assurance study, and on a panel of selected swine influenza viruses. 
Clinical applicability was demonstrated on the first imported cases 
of pandemic H1N1 influenza in Germany, and by testing more 
than 200 confirmed cases later in the pandemic without any 
false positive or negative results. Interestingly rather low virus 
concentrations were measured by the pandemic H1N1 influenza-
specific real-time RT-PCR, compared to viral loads seen in seasonal 
influenza [25,26]. It remains unclear if this is related to the host 
or propensity of the virus itself.
We have also shown in this study that a broad-range influenza 
A assay recommended by WHO and based on the MA gene had 
the same high sensitivity as the HA-based pandemic H1N1 
influenza-specific assay and can be used for simultaneous 
detection of influenza A(H1N1)v virus and seasonal strains [12]. 
It can thus serve as a confirmatory test and for discriminating 
influenza A(H1N1)v virus from seasonal strains. Both assays were 
developed to allow for parallel testing on a single real-time PCR 
instrument, reducing the time of turnover significantly [27]. Use 
of the combined assays facilitates decentralised testing in clinical 
laboratories, which is necessary when the demands for testing will 
exceed the capacities of reference laboratories during the upcoming 
pandemic [20,28]. In this respect, it is important to mention that 
the validation data presented in this report have been generated by 
five different laboratories that had obtained the assays in form of 
protocols and pre-evaluated oligonucleotides. Recent experiences 
during the epidemics of severe acute respiratory syndrome (SARS) 
and chikungunya disease have demonstrated that rapid provision 
of pre-formulated diagnostic assays can facilitate immediate 
diagnostic capacity building [13,14,29]. 
To conclude, we could demonstrate that the testing alogrithm 
proposed here is a feasible approach and might assist public health 
laboratories in the upcoming influenza season.
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